Insights

white paper

While large molecules continue to advance in drug development pipelines, small molecule Active Pharmaceutical Ingredients (APIs) still retain their historical dominance among new drug applications (NDAs). However, the last few years have seen the lin...

white paper

Ensuring the safety and efficacy of pharmaceutical products is paramount in the healthcare industry, making the FDA's Quality Management Maturity (QMM) program and CDER's proposed rating system crucial for Contract Development and Manufacturing Organ...

white paper

Advances in disease biology have led to the burgeoning development of bispecific antibodies (BsAbs), which are synthetic proteins capable of targeting two discrete epitopes from different antigens. Their bispecific functionality offers promising ther...

article

Lyophilization, also known as freeze-drying, is often a crucial step in the manufacturing process of biologics drug products. Biologics are large, complex molecules used to treat various diseases, including cancer, autoimmune disorders, and rare gene...

white paper

In the fall of 2021, the Delta variant of SARS-CoV-2 was the dominant strain in the US, being both more contagious than previous variants and more likely to lead to “long COVID” than subsequent Omicron variants. Here we describe the discovery and...

article

To say that “our lives are busier than ever” would be a redundant statement. The good news is: we still have 24 hours in each day! Curia’s Director, Learning & Development, Terri Souder-Basa put together a practical guide on how to overcome a...

article

The right choice of organic reagents early in the synthesis can smooth the path and expediate the journey of lead- to- candidate identification. Curia can produce the green and versatile reagent T3P in a superior purity – and give researchers the f...

white paper

A large portion of innovative companies are in discovery, preclinical or early clinical stages with therapeutics aimed at oncology and infectious diseases. There is promising growth in overall biologics therapies, driven by increased funding and grow...

white paper

With experience in both chemistry and biologics, Curia is uniquely positioned to provide mRNA drug development solutions spanning discovery and engineering, mRNA drug substance formulation, and fill-finish and manufacturing of lipids and nucleosides.

article

When a drug substance requires a parenteral formulation to administer it, there are key factors to consider when choosing the ideal CDMO partner.

white paper

Traditionally, early-stage and late-stage process development have been done separately, with early-stage mostly focused on material production and late-stage on process intensification. As more molecules in development fall under an orphan or fast-t...

white paper

The number of FDA-approved monoclonal antibodies (mAbs) continues to grow, while those in late-stage development rose more than 30% between 2021 and 2022.